“ RECOVER-1 Phase 3 global trial successfully met all primary and secondary endpoints with statistically significant reductions across all major symptom domains in schizophrenia “ “ Initiation of...
CUPERTINO, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (Reviva or the Company), a late-stage pharmaceutical company developing therapies that...
Reviva to Present Ph 3 Data for Brilaroxazine in Schizophrenia at Meeting
Reviva to Present at the UBS Virtual CNS Day
Reviva to Present at the 36th Annual ROTH Conference
CUPERTINO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (œReviva or the œCompany), a late-stage pharmaceutical company developing therapies that...
CUPERTINO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) (Reviva or the Company), a late-stage pharmaceutical company developing therapies that...
“ Schizophrenia late-stage clinical program advances with positive topline Phase 3 data, successful ongoing enrollment in open label extension (OLE) trial, and positive drug-drug interaction data...
CUPERTINO, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (œReviva or the œCompany), a late-stage pharmaceutical company developing therapies that...